NCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
Clinical Trials
17 trialsNCT07190833 2026-04-09
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Recruiting
NCT05853458 2026-04-07
HU-F-AIM
Novartis
Phase 4 Terminated
NCT07170592 2026-04-07
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT06093672 2026-03-25
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT06871410 2026-03-24
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06063317 2026-03-06
OASIS
Imugene Limited
Phase 1 Terminated
NCT07033598 2026-03-05
PROSPERA
Theradex
Phase 2 Recruiting
NCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT05020652 2025-12-17
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT06005324 2025-06-08
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed